References for Caught in the Crossfire

1. Nelson  HD (2004) Commonly used types of postmenopausal  estrogen for treatment of hotflashes: Scientific review. JAMA 291:1610-1620

2. Hersh AL et al.(2004) National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA 291: 47-53

3.    http://www.nhlbi.nih.gov/whi/

4. Speroff L(2006) The WHI Studies on Calcium and Vitamin D. OB/GYN Clinic Alert;22: 93-95

5. Jackson RD et al (2006) Calcium plus Vitamin D supplementation and the risk of fractures. NEJM; 354:669-683

6. Klaiber EL. Et al.(2005) A critique of the Women's Health Initiative hormone therapy study. Fertilty and Sterility;84:1589-1598

7. Pfeilschifter J et al. (2002) Changes in Proinflammatory Cytokine Activity after Menopause.  Endo Reviews;23:90-119

8. Rossouw JE et al. (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA; 297: 1465-1477

9. Phillips LS et al. (2005)Postmenopausal hormone therapy :critical reappraisal and a unified hypothesis. Fertility and Sterility;83:558-564

10. Writing Group for Women's Health Initiative Investigators.(2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the  Women's Health Initiative randomized control study. JAMA;288:321-33

11. Manson JE et al. (2007) Estrogen therapy and coronary-artery calcification. NEJM;356:2591-2602

12. Clarkson TB (2007) The effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause;14:373-384

13. Phillips LS et al. (2005) Postmenopausal hormone therapy:critical reappraisal and a unified hypothesis. Fertility and Sterility;83:558-564

14. Merck and Schering-Plough (2008) The ENHANCE Study.

15. Speroff L(2007) More Good News from the WHI. OB/GYN Clinic Alert;24:25-27

16. Umetani M et al. (2007) 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. NatMed;http://www.natur.com/naturemedicine.1-8

17. Winslow R(2007) Report Sheds Light on Hormone Therapy. The Wall Street Journal, Monday,September 17.

18. DuSell C et al.(2008) 27-Hydroxycholesterol is an endogenous  Selective Estrogen Receptor Modulator (SERM). Molecular Endo;22:65-77

19. Wright JV. Natural Hormone Replacement. Smart Publications.1997,page 49

20. Zhang et al.(1999).The major metabolite of equilin,4-hydroxyequilin, autooxidizes to an o-quinone which isomerizes to the potent 4-hydroxequilenin-o-quinone. Chemical Research in Toxicology;12:204-13

21. Cavalieri E et al.(2006) Catechol Quinones of Estrogen in the Initiation of Breast, Prostate, and Other Human Cancers.
Ann N.Y. Acad.Sci.;1089:286-301

22. Paruthyiyil S et al.(2004) Estrogen Receptor b Inhibits Human Breast Cancer Cell Proliferation and Tumor Formation by Causing a G₂ Cell Arrest. Cancer Research;64:423-428

23. Schumacher M et al. (2007). Novel Perspectives for Progesterone in Hormone Replacement Therapy, with Special Reference to the Nervous System. Endo Reviews;28:387-439

24. Canonico M et al.(2007). Hormone therapy and venous thromboembolism among postmenopausal women: impact of estrogen administration and progestagens: The ESTHER Study. Circulation:115:840-845

25. De Vivo I et al.(2003) A Functional Polymorphism in the Progesterone Receptor Gene is Associated with an Increase in Breast Cancer Risk. Cancer Research;63:5236-5238

26. Buchanan G et al.(2005) Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Research; 65:8487-96

27. Mueck AO et al.(2003) Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact on continuous progestogen addition. Climacteric; 6:221-227

28. Fournier A et al. (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N. Breast Cancer Res Treat; 107:103-111

29. Wiebe JP et al.(2000) The 4-Pregnene and 5a-Pregnane Progesterone Metabolites Formed in Nontumorous and Tumorous Breast Tissue Have Opposite Effects on Breast Cell Proliferation and Adhesion. Cancer Research;60:936-943

30. personal communication Wiebe JP(2008)

31. Birrell SN et al.(1995) Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J.Clin.Oncol.;7:1572

32. FDA News 9 Jan.(2008)

33. McWherter JF. Avoiding Breast Cancer While Balancing Your Hormones. A.E.Rosebud. 2005

34. Reiss U. The Natural Superwoman. Penquin Group.2007.

35. Lauritzen C.(1987) Results of a 5 years prospective study of estriol succinate treatment in patients with climacteric complaints. Horm Metab Res; 19: 579-84

36. Stampfer MJ et al.(1985) A prospective study of postmenopausal estrogen  therapy and coronary heart disease. NEJM; 313: 663-71

37. Mueck AO et al.(2006) The Role of Progestins in Breast Cancer: Experimental vs. Clinical Data.
Menopausal Medicine;14:1-6

38.Wiley T.S. Sex,Lies, and Menopause. HarperCollins. 2003

39. personal communication Wiley T.S. 2007

40. Grodstein F.et al. (2000) A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med; 133:933-41

41. Phillips LS et al. (2005) Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertility and Sterility;83: 558-565

42. Berga SL et al.(2007) Understanding Hormone action: Does Route of Administration Matter? OB/GYN Clinical Alert;24:20

43. Straczek C, et al.(2005) Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulaton;112:3495-3500

44. Lundstrom E et al.(2001) Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Climateric;4:42-8

45. Csizmadi I et al.(2004) The effects  of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women. Br J Cancer;90:76-81

46. Berga S (2007) Editorial: Does estrogen use support cognition in postmenopausal women. Menopause;14:163-165

47. Shumaker S et al.(2003) Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women. JAMA; 289: 2651-2662

48. Rapp S et al.(2003) Effect of Estrogen Plus Progestin on Global Function in Postmenopausal Women. JAMA;289:2663-2672

49. Zandi PP et al.(2002) Hormone Replacement and incidence of Alzheimer disease in Cache County Study. JAMA;288:2123-9

50. Dunkin J et al.(2005) Reproductive events modify the effects of estrogen replacement therapy on cognition in healthy postmenopausal women. Pscyhoneuroendocrinology;30:284-296

51. Bagger YZ et al.(2005) Early menopause hormone therapy may prevent cognitive impairment in later life. Menopause;12:12-17

52. Nordell VL et al.(2003) Differential effects of estrogen in the injured forebrain of young and reproductive senescent animals. Neurobiol. Aging; 24:733-43

53. Klaiber EL. Hormones of the Mind. HarperCollins.2001

54. Vermer SE et al.(2003) Silent brain infarcts and the risk of dementia and cognitive decline. NEJM;384:1215-1222

55. Singh M et al.(2008) Estrogens and progesterone as neuroprotectants: what animal models teach us. Frontiers in Bioscience; 13:1083-1089

56. Anderson GL et al.(2006)Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas;55:103-15

57. Speroff L(2006) Breast Cancer Risk in the WHI Estrogen-Progestin Trial Arm. OB/GYN Clinical Alert;22:39-40

58. Chlebowski RT, et al.(2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized Trial. JAMA;289:3243-3253

59. Sellers TA et al.(1997) The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med;127:973-80

60. Dupont WD et al.(1999) Estrogen replacement therapy in women with a history of proliferative breast disease.Cancer;85:1277-83

61. Brewster AM et al.(2007) Relationship Between Epidemiologic Risk Factors and Breast Cancer Recurrence. J. Clinical Oncology;28:438-44

62. Mor G et al.(1998) Macrophages, estrogen, and the microenvironment  of breast cancer. J. Steroid Biochem Mol Biol.;67:403-11

63. Grodstein F. et al.(1997) Postmenopausal hormone therapy and mortality. NEJM;336:1769-75

64. The Women's Health Initiative Steering Committee. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA;291:1701-1712

65. Stefanick ML et al.(2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA;295:1647-1657

66. Soto AM et al.(2001) The Two Faces of Janus:Sex Steroids as Mediators of Both Cell Proliferation and Cell Death. J. Natl. Cancer Inst.93:1673-5

67. Song RX et al.(2001) Effect of long-term estrogen deprivation on apoptotic responses of breast cells to 17b-estradiol. J. Natl. Cancer Inst.93:1741-23

68. Savarese TM et al.(2006). Normal Breast Stem Cells, Malignant Breast Stem Cells, and the Perinatal Origin Of Breast Cancer. Stem Cells Review; 2:103-110

69. O'Meara ES et al. (2001). Hormone replacement therapy after diagnosis of breast cancer in relation to recurrence and mortality. J. Natl. Cancer Inst. 93:754-762

70. Kerlikowske K et al.(2007). Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J.Natl.Cancer Inst.99:1335-9

71. personal communication Vivelle(2008)

72. Gambrell RD. et al.(2007) Menopause Hormone Therapy:Calculating Risks and Benefits, Letters to the Editor; Obstetrics and Gynecology;6:1455

73. Bush TL et al.(2001) Hormone Replacement Therapy and Breast Cancer: A Qualitative Review. Obstetrics and Gynecology;98:498-508

74. Parl F. Estrogens, Estrogen Receptor and Breast Cancer. IOS. 2000

75. Zahid M et al.(2007) Inhibition of Depurinating Estrogen-DNA Adduct Formation by Natural Compounds. Chem Res Toxicol.;20:1947-53

76. Heiss G et al.(2008)Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. JAMA;299:1036-1045

77. Hulley S et al.(2002) Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy. JAMA;288:58-66

78. Kawai H et al.(2005)Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin. Cancer Res.;11:5084-9

79. Ross H, Bonomi P, Langer M, et al.(2007) Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaive patients with advanced NSCLC and poor performance status (PS2). J Clin Oncol.;24: 7039

80. Barbieri R (2006) Is Premarin actually a SERM. OBG Management.18:11